Dr. Rajeev V. Kumar

Neonatology | Pediatrics
1900 W Harrison St, 
Chicago, IL 
Clinical Trials:Currently Recruiting for 2 Trials
Accepting New Patients
Offers Telehealth
1900 W Harrison St, 
Chicago, IL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Rajeev Kumar is a Neonatologist and a Pediatrics provider in Chicago, Illinois. His top areas of expertise are Meconium Aspiration Syndrome, Gliomatosis Cerebri, and Transient Familial Hyperbilirubinemia. Dr. Kumar is currently accepting new patients.

His clinical research consists of co-authoring 240 peer reviewed articles and participating in 17 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Neonatology
Pediatrics
Licenses
Pediatrics in IL
Languages Spoken
English
Hindi
Punjabi
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO

Locations

1900 W Harrison St, Chicago, IL 60612
Other Locations
2233 W Division St, Chicago, IL 60622

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

17 Clinical Trials

HDClarity: a Multi-site Cerebrospinal Fluid Collection Initiative to Facilitate Therapeutic Development for Huntington's Disease
HDClarity: a Multi-site Cerebrospinal Fluid Collection Initiative to Facilitate Therapeutic Development for Huntington's Disease
Enrollment Status: Recruiting
Publish Date: December 19, 2025
Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort
Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort
Enrollment Status: Recruiting
Publish Date: February 28, 2024
A Phase 2A, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of PTC518 in Subjects With Huntington's Disease
A Phase 2A, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of PTC518 in Subjects With Huntington's Disease
Enrollment Status: Completed
Publish Date: January 13, 2026
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of BIIB122 in Participants With Parkinson's Disease
A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of BIIB122 in Participants With Parkinson's Disease
Enrollment Status: Active_not_recruiting
Publish Date: October 23, 2025
Intervention Type: Drug
Study Phase: Phase 2
A Multicenter, Randomized, Active-controlled, Double-blind, Double-dummy, Parallel-group Clinical Trial, Investigating the Efficacy, Safety, and Tolerability of Continuous Subcutaneous ND0612 Infusion in Comparison to Oral IR-LD/CD in Subjects With Parkinson's Disease Experiencing Motor Fluctuations (BouNDless)
A Multicenter, Randomized, Active-controlled, Double-blind, Double-dummy, Parallel-group Clinical Trial, Investigating the Efficacy, Safety, and Tolerability of Continuous Subcutaneous ND0612 Infusion in Comparison to Oral IR-LD/CD in Subjects With Parkinson's Disease Experiencing Motor Fluctuations (BouNDless)
Enrollment Status: Active_not_recruiting
Publish Date: May 21, 2025
Intervention Type: Drug, Combination product
Study Drugs: ND0612 Solution, Carbidopa, Levodopa
Study Phase: Phase 3
Phase 2a Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic (PD) Study of Intravenous ANX005 in Subjects With Amyotrophic Lateral Sclerosis (ALS)
Phase 2a Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic (PD) Study of Intravenous ANX005 in Subjects With Amyotrophic Lateral Sclerosis (ALS)
Enrollment Status: Completed
Publish Date: January 06, 2025
Intervention Type: Drug
Study Drug: ANX005
Study Phase: Phase 2
A Randomized, Double-blind, Placebo-Controlled, 2-Period Crossover, Phase 2 Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral TAK-071 in Parkinson Disease Patients With Cognitive Impairment and an Elevated Risk of Falls
A Randomized, Double-blind, Placebo-Controlled, 2-Period Crossover, Phase 2 Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral TAK-071 in Parkinson Disease Patients With Cognitive Impairment and an Elevated Risk of Falls
Enrollment Status: Completed
Publish Date: May 14, 2024
Intervention Type: Drug
Study Drug: TAK-071
Study Phase: Phase 2
A Multicenter, Non-Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Orally Administered ENT-01 in Improving Constipation and Neurologic Symptoms in Patients With Parkinson's Disease and Constipation Over a 14-week Period
A Multicenter, Non-Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Orally Administered ENT-01 in Improving Constipation and Neurologic Symptoms in Patients With Parkinson's Disease and Constipation Over a 14-week Period
Enrollment Status: Terminated
Publish Date: March 19, 2024
Intervention Type: Drug
Study Drug: ENT-01
Study Phase: Phase 2
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate Safety, Tolerability and Efficacy of Orally Administered ENT-01 for the Treatment of Parkinson's Disease-Related Constipation (KARMET)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate Safety, Tolerability and Efficacy of Orally Administered ENT-01 for the Treatment of Parkinson's Disease-Related Constipation (KARMET)
Enrollment Status: Completed
Publish Date: February 20, 2024
Intervention Type: Drug
Study Drug: ENT-01
Study Phase: Phase 2
Cutaneous Phosphorlyated α-synuclein Detection as a Biomarker of Synucleinopathy
Cutaneous Phosphorlyated α-synuclein Detection as a Biomarker of Synucleinopathy
Enrollment Status: Completed
Publish Date: January 03, 2024
Intervention Type: Diagnostic test
A Multi-Center, Single-Dose, Multiple-Dose, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered ENT-01 for the Treatment of Parkinson's Disease Related Constipation
A Multi-Center, Single-Dose, Multiple-Dose, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered ENT-01 for the Treatment of Parkinson's Disease Related Constipation
Enrollment Status: Completed
Publish Date: December 27, 2023
Intervention Type: Other, Drug
Study Phase: Phase 1/Phase 2
A Phase 2a Open Label Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous ANX005 in Subjects With, or at Risk for, Manifest Huntington's Disease
A Phase 2a Open Label Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous ANX005 in Subjects With, or at Risk for, Manifest Huntington's Disease
Enrollment Status: Completed
Publish Date: January 31, 2023
Intervention Type: Drug
Study Drug: ANX005
Study Phase: Phase 2
Indirect and Out-of-Pocket Costs of Huntington's Disease in the United States
Indirect and Out-of-Pocket Costs of Huntington's Disease in the United States
Enrollment Status: Completed
Publish Date: September 21, 2022
Intervention Type: Behavioral
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study, With an Active-Treatment Dose-Blinded Period, to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Subjects With Parkinson's Disease
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study, With an Active-Treatment Dose-Blinded Period, to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Subjects With Parkinson's Disease
Enrollment Status: Terminated
Publish Date: February 28, 2022
Intervention Type: Drug
Study Drug: BIIB054
Study Phase: Phase 2
Effect of LY3154207 on Cognition in Mild-to-Moderate Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB)
Effect of LY3154207 on Cognition in Mild-to-Moderate Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB)
Enrollment Status: Completed
Publish Date: July 23, 2021
Intervention Type: Drug
Study Phase: Phase 2
A 4-Week, Double-blind, Placebo-controlled, Randomized, Multicenter, Crossover Study of the Safety, Efficacy, and Pharmacokinetics of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate Hydrochloride] in Subjects With Parkinson's Disease and Excessive Sleepiness
A 4-Week, Double-blind, Placebo-controlled, Randomized, Multicenter, Crossover Study of the Safety, Efficacy, and Pharmacokinetics of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate Hydrochloride] in Subjects With Parkinson's Disease and Excessive Sleepiness
Enrollment Status: Completed
Publish Date: January 09, 2020
Intervention Type: Drug, Other
Study Phase: Phase 2
FuRST 2.0: Cognitive Pre-Testing Study for a New Functional Rating Scale for Use in Huntington's Disease
FuRST 2.0: Cognitive Pre-Testing Study for a New Functional Rating Scale for Use in Huntington's Disease
Enrollment Status: Completed
Publish Date: August 08, 2017
Intervention Type: Behavioral
View 15 Less Clinical Trials

234 Total Publications

Harnessing data and control with AI/ML-driven polymerization and copolymerization.
Harnessing data and control with AI/ML-driven polymerization and copolymerization.
Journal: Faraday discussions
Published: October 14, 2025
Similar Doctors
Expertise in
4
conditions
Dr. Aloka L. Patel
Neonatology | Pediatrics
Expertise in
4
conditions
Dr. Aloka L. Patel
Neonatology | Pediatrics
1653 W Congress Pkwy, 
Chicago, IL 
 (0.3 miles away)
312-942-7154
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Aloka Patel is a Neonatologist and a Pediatrics provider in Chicago, Illinois. Dr. Patel is highly rated in 4 conditions, according to our data. Her top areas of expertise are Necrotizing Enterocolitis, Premature Infant, Bronchopulmonary Dysplasia, and Viral Gastroenteritis. Dr. Patel is currently accepting new patients.

Expertise in
6
conditions
Dr. Aaron E. Hamvas
Neonatology
Expertise in
6
conditions
Dr. Aaron E. Hamvas
Neonatology
225 E Chicago Ave, 
Chicago, IL 
 (3.1 miles away)
312-227-4190
Languages Spoken:
English
See accepted insurances

Aaron Hamvas is a Neonatologist in Chicago, Illinois. Dr. Hamvas is highly rated in 6 conditions, according to our data. His top areas of expertise are Premature Infant, Infant Respiratory Distress Syndrome, Bronchopulmonary Dysplasia, and High Blood Pressure in Infants.

Expertise in
7
conditions
Dr. Lynn M. Yee
Neonatology | Obstetrics and Gynecology
Expertise in
7
conditions
Dr. Lynn M. Yee
Neonatology | Obstetrics and Gynecology
675 N St Clair St Ste 14-200, Galter Pavilion, 
Chicago, IL 
 (3.5 miles away)
312-695-7542
Experience:
18+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Lynn Yee is a Neonatologist and an Obstetrics and Gynecologist in Chicago, Illinois. Dr. Yee has been practicing medicine for over 18 years is highly rated in 7 conditions, according to our data. Her top areas of expertise are Gestational Diabetes, Newborn Low Blood Sugar, HIV/AIDS, and Postpartum Depression.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kumar's expertise for a condition
ConditionClose
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile